Asana Biosciences To Provide First Presentation Of Pre-Clinical Data On Its Novel ERK 1/2 Inhibitor Program At The AACR Annual Meeting

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Asana BioSciences, LLC announced today that it will present preclinical data regarding its product candidate, ASN007A, at the American Association for Cancer Research (AACR) Annual Meeting, being held in New Orleans, Louisiana, from April 16-20, 2016. The presentation details are as follows:
MORE ON THIS TOPIC